Moderna, Inc. (NASDAQ:MRNA) Q4 2023 Earnings Conference Call February 22, 2024 8:00 AM ET

Company Participants

Stéphane Bancel - Chief Executive Officer

Stephen Hoge - President

Jamey Mock - Chief Financial Officer

Lavina Talukdar - Senior Vice President & Head of Investor Relations

Conference Call Participants

Michael Yee - Jefferies

Gena Wang - Barclays

Eli Merle - UBS

Hartaj Singh - Oppenheimer

Luca Issi - RBC Capital

Elizabeth Webster - Goldman Sachs

Alex Hammond - Bank of America

Terence Flynn - Morgan Stanley

Jessica Fye - J.P. Morgan

Evan Wang - Guggenheim Securities

Operator

Good day, and thank you for standing by. Welcome to the Moderna Fourth Quarter 2023 Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. [Operator Instructions]. Please be advised, today's conference is being recorded.

I would now like to hand the conference over to your speaker today, Lavina Talukdar. Please go ahead.

Lavina Talukdar

Thank you, Kevin. Good morning, everyone, and thank you for joining us on today's call to discuss Moderna's fourth quarter and full year 2023 financial results and business updates. You can access the press release issued this morning as well as the slides that we'll be reviewing by going to the investor section of our website. On today's call are Stéphane Bancel, our Chief Executive Officer; Stephen Hoge, our President; and Jamey Mock, our Chief Financial Officer.

Before we begin, please note that this conference call will include forward-looking statements made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Please see slide two of the accompanying presentation and our SEC filings for important risk factors that could cause our actual performance and results to differ materially from those expressed or implied in these forward-looking statements.

With that, I'll turn it over to Stéphane.

Stéphane Bancel

Thank you, Lavina. Good morning or good afternoon, everyone. Thank you for joining us today. I will start with a review of 2023. Jamey will then present our financial results. Stephen will then review our late-stage clinical programs, and I will close by sharing our 2024 priorities.

Let me start with our mission, Moderna's commitment to deliver the greatest possible impact to people through mRNA medicine. In 2023, every member of the Moderna team helped to advance our mission, which is a driving force that motivates our team every single day. We impacted more than 100 million people around the world and we advanced our development pipeline across all of our franchises, including infectious disease, oncology, and rare disease.